Flamyd 60 ml is an antiprotozoal and antibacterial agent from the imidazole class. It is primarily indicated for infections caused by anaerobic bacteria and protozoa, including:
Prevention of post-operative infections caused by anaerobes such as Bacteroides species and anaerobic streptococci.
Treatment of serious anaerobic infections, including:
Septicaemia and bacteraemia
Peritonitis
Brain abscess
Pelvic abscess and pelvic cellulitis
Post-operative wound infections
Urogenital infections:
Trichomoniasis
Bacterial vaginosis (non-specific vaginitis)
Protozoal infections:
Amoebiasis (intestinal, extra-intestinal, and asymptomatic cyst carriers)
Giardiasis
Oral and dental infections:
Acute ulcerative gingivitis
Acute dental infections due to anaerobic organisms
Skin and soft tissue infections:
Anaerobically infected leg ulcers and pressure sores
Special conditions:
Antibiotic-associated pseudomembranous colitis
Surgical prophylaxis to prevent anaerobic infections in high-risk surgeries
Amoebicides
Anti-diarrhoeal antiprotozoal
Flamyd 60 ml works by metabolic reduction of its 5-nitro group by anaerobic organisms, producing a reactive form that interacts with DNA. This inhibits nucleic acid synthesis, resulting in bactericidal and protozoacidal effects.
Oral Tablets/Suspension: Doses depend on age and condition. Adults: 200–400 mg 2–3 times daily; single doses of 2 g for specific infections. Pediatric doses are weight-based.
Vaginal Gel: One applicator (~5 g) once or twice daily for 5 days; administer at bedtime if once daily.
Suppository: Adults: 1 g every 8–12 hours; Children: 500 mg based on age/weight.
IV Infusion: Adults & children >12 yrs: 500 mg every 8 hours (max 4 g/24h); Children <12 yrs: 7.5 mg/kg every 8 hours.
Disulfiram & Alcohol: Risk of disulfiram-like reaction (flushing, vomiting, tachycardia).
Warfarin: May potentiate anticoagulant effect; monitor prothrombin time.
Lithium & Cyclosporin: May increase serum levels, monitor closely.
Phenytoin/Phenobarbital: May reduce plasma levels of Flamyd.
5-Fluorouracil & Busulfan: Altered metabolism may increase toxicity.
Hypersensitivity to metronidazole or other nitroimidazole derivatives.
Common: metallic taste, nausea, vomiting, diarrhea, drowsiness, rashes.
Monitor blood counts with prolonged therapy.
Use caution in hepatic encephalopathy; reduce dose if necessary.
May darken urine during treatment.
Patients should avoid alcohol during therapy and for at least 24 hours after the last dose.
FDA Category B: Use only if clearly needed.
Excreted in human milk; caution when administered to nursing women.
Pediatric doses are weight-based; adjust in hepatic impairment.
No routine adjustment required for renal impairment; re-administer post-hemodialysis if needed.
Store below 30°C, protected from light, and out of reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet